Matrix metalloproteinase inhibitors: A patent review (2011-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 9, 2014, Pages 1039-1052

  Li, Nian Guang ^a   Tang, Yu Ping ^a   Duan, Jin Ao ^a   Shi, Zhi Hao ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Diagnostic imaging agents; Drug design; Inhibitor selectivity; MMPs

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; BATIMASTAT; CIPEMASTAT; ILOMASTAT; KB R 7785; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; PRINOMASTAT; REBIMASTAT; RO 2060222; RO 282653; TANOMASTAT; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE;

DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; NONHUMAN; PATENT; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; EXTRACELLULAR MATRIX; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; DRUG DESIGN; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PATENTS AS TOPIC; TISSUE DISTRIBUTION;

EID: 84906228466     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.937424     Document Type: Review

References (91)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
2. Norman P. Selective MMP-12 inhibitors: WO-2008057254. Expert Opin Ther Pat 2009;19:1029-34
3. Li NG, Shi ZH, Tang YP, et al. Selective matrix metallo proteinase inhibitors for cancer. Curr Med Chem 2009;16:3805-27
4. Winum JY, Scozzafava A, Montero JL, et al. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Pat 2006;16:27-47
5. Itoh Y. Metalloproteinase binding proteins: WO2009097397. Expert Opin Ther Pat 2010;20:1091-5
6. Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets 2013;14:325-34
7. Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 2009;21:1323-33
8. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501
9. Wilson LJ, Wang B, Yang SM, et al. Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy. Bioorg Med Chem Lett 2011;21:6485-90
10. Shi ZH, Li NG, Shi QP, et al. Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 2013;23:1206-11
11. Freskos JN, Asmelash B, Gaston KR, et al. Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes. Bioorg Med Chem Lett 2013;23:5566-70
12. Li Y, Zhang J, Xu W, et al. Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I). Bioorg Med Chem 2010;18:1516-25
13. Wang J, Medina C, Radomski MW, et al. N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem 2011;19:4985-99
14. Topai A, Breccia P, Minissi F, et al. In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors. Bioorg Med Chem 2012;20:2323-37
15. Wang L, Li X, Zhang S, et al. Natural products as a gold mine for selective matrix metalloproteinases inhibitors. Bioorg Med Chem 2012;20:4164-71
16. Cheng XC, Wang RL, Dong ZK, et al. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on Ltyrosine scaffold. Bioorg Med Chem 2012;20:5738-44
17. Tauro M, Laghezza A, Loiodice F, et al. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg Med Chem 2013;21:6456-65
18. Nuti E, Casalini F, Santamaria S, et al. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem 2011;46:2617-29
19. Wang J, O'Sullivan S, Harmon S, et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem 2012;55:2154-62
20. Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012;55:7875-82
21. Gooyit M, Song W, Mahasenan KV, et al. O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. J Med Chem 2013;56:8139-50
22. Li NG, Tang YP, Duan JA. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158). Expert Opin Ther Pat 2013;23:669-75
23. Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res 2003;15:364-72
24. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasias side effects. J Biol Chem 2007;282:27781-91
25. Li NG, Shi ZH, Tang YP, et al. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001
26. Schnute ME, O'Brien PM, Nahra J, et al. Discovery of (pyridin-4-yl)- 2Htetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett 2010;20:576-80
27. Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3557-60
28. Kolodziej SA, Hockerman SL, DeCrescenzo GA, et al. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3561-4
29. Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010;20:5039-43
30. Tommasi RA, Weiler S, McQuire LW, et al. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. Bioorg Med Chem Lett 2011;21:6440-5
31. Roth J, Minond D, Darout E, et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011;21:7180-4
32. La Pietra V, Marinelli L, Cosconati S, et al. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J Med Chem 2012;47:143-52
33. Taylor SJ, Abeywardane A, Liang S, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem 2011;54:8174-87
34. Gege C, Bao B, Bluhm H, et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 2012;55:709-16
35. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42
36. Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med 2011;21:112-18
37. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005;50:329-39
38. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005;25:6401-8
39. Lorenzl S, Calingasan N, Yang L, et al. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Med 2004;5:119-32
40. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003;43:191-6
41. Jung SS, Zhang W, Van Nostrand WE. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003;85:1208-15
42. Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003;2:747-56
43. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004;113:1447-55
44. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002;106:3024-30
45. Antoniu SA. Matrix metalloproteinase inhibitors for chronic obstructive pulmonary disease. Drugs Future 2012;37:523-9
46. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27
47. Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-53
48. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-9
49. Bond M, Murphy G, Bennett MR, et al. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domaindependent type II apoptotic pathway. J Biol Chem 2002;277:13787-95
50. Ahonen M, Poukkula M, Baker AH, et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003;22:2121-34
51. Jain P, Saravanan C, Singh SK. Sulphonamides: deserving class as MMP inhibitors? Eur J Med Chem 2013;60:89-100
52. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203
53. Cheng XC, Wang Q, Fang H, et al. Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr Med Chem 2008;15:368-73
54. Jin Y, Roycik MD, Bosco DB, et al. Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem 2013;56:4357-73
55. Hugenberg V, Riemann B, Hermann S, et al. Inverse 1,2,3-triazole-1-yl- ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation. J Med Chem 2013;56:6858-70
56. Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994;263:375-7
57. Gooley PR, O'Connell JF, Marcy AI, et al. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol 1994;1:111-18
58. Czarny B, Stura EA, Devel L, et al. Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem 2013;56:1149-59
59. Zhang Y, Gu Y, Lee HM, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012;19:4348-58
60. Zhong HA, Arbiser J, Bowen JP. Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors. Curr Pharm Des 2013;19:4701-13
61. Shah PK, Wilkin DJ, Doherty TM, et al. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin Ther Pat 2002;12:665-707
62. Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98
63. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early-and late-phase development of neuropathic pain. Nat Med 2008;14:331-6
64. Tallahassee FL (US). Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors. US2011144179A1; 2011
65. Jin UH, Lee JY, Kang SK, et al. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci 2005;77:2760-9
66. Institute of Botany in Jiangsu Province. New honeysuckle chlorogenic acid ester saponin as well as preparation method and use thereof. CN102050862A; 2011
67. Glaxo Group Ltd. Matrix metalloproteinase inhibitors. AU2011202994A1; 2011
68. Vernalis (Oxford) Ltd, Cambridge (GB); Laboratoires Serono S. A., Aubonne (CH). Oxa-and thiadiazoles and their use as metalloproteinase inhibitors. US2011086893A1; 2011
69. Brooks PM. Impact of osteoarthritis on individuals and society: how much disabilityi Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7
70. Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009;60:2008-18
71. Settle S, Vickery L, Nemirovskiy O, et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010;62:3006-15
72. Abbott Laboratories. Isoxazolines as therapeutic agents. WO2012151158A1; 2012
73. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038943A1; 2012
74. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038942A1; 2012
75. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038944A1; 2012
76. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012014114A1; 2012
77. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. TW201336829A; 2013
78. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. AU2013200728A1; 2013
79. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990;87:5578-82
80. Janssen Pharmaceutica Nv, BE. Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases. WO2013003360; 2013
81. Westfälische Wilhelms-Universität Münster 48149 Münster (DE), Siemens Medical Solutions USA, Inc. Malvern, PA 19355 (US). Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof. EP2644601A1; 2011
82. Mallinckrodt, Inc. MMP-targeted therapeutic and/or diagnostic nanocarriers. WO2013082389A1; 2013
83. Universitaet Muenster. Compounds with matrix-metalloproteinase inhibitory activity. WO2013010573A1; 2013
84. Cordeiro MF. Beyond Mitomycin: TGFbeta and wound healing. Prog Retin Eye Res 2002;21:75-89
85. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res 2002;74:337-47
86. Di Girolamo N, Chui J, Coroneo MT, et al. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res 2004;23:195-228
87. University of East Anglia (GB). Treatment of fibrotic eye disorders using an MMP2 inhibitor. US2011236395A1; 2011
88. Conatus Pharmaceuticals, Inc. Combination therapy for the treatment of liver diseases. US2011212056A1; 2011
89. Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010;45:351-423
90. Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 2007;12:640-6
91. Krzeski P, Buckland-Wright C, Bálint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebocontrolled study. Arthritis Res Ther 2007;9:R109